Exploring the two-gene ratio in breast cancer—independent roles for HOXB13 and IL17BR in prediction of clinical outcome
10.1007/s10549-007-9541-8
Crossref journal-article
Springer Science and Business Media LLC
Breast Cancer Research and Treatment (297)
Bibliography

Jerevall, P.-L., Brommesson, S., Strand, C., Gruvberger-Saal, S., Malmström, P., Nordenskjöld, B., Wingren, S., Söderkvist, P., Fernö, M., & Stål, O. (2007). Exploring the two-gene ratio in breast cancer—independent roles for HOXB13 and IL17BR in prediction of clinical outcome. Breast Cancer Research and Treatment, 107(2), 225–234.

Authors 10
  1. Piiha-Lotta Jerevall (first)
  2. Sara Brommesson (additional)
  3. Carina Strand (additional)
  4. Sofia Gruvberger-Saal (additional)
  5. Per Malmström (additional)
  6. Bo Nordenskjöld (additional)
  7. Sten Wingren (additional)
  8. Peter Söderkvist (additional)
  9. Mårten Fernö (additional)
  10. Olle Stål (additional)
References 30 Referenced 52
  1. Early Breast Cancer Trialists’ Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472):1687–1717 (10.1016/S0140-6736(05)66544-0) / Lancet by Early Breast Cancer Trialists’ Collaborative Group (2005)
  2. Sorlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98(19):10869–10874 (10.1073/pnas.191367098) / Proc Natl Acad Sci USA by T Sorlie (2001)
  3. Gruvberger S, Ringner M, Chen Y et al (2001) Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res 61(16):5979–5984 / Cancer Res by S Gruvberger (2001)
  4. Sotiriou C, Neo SY, McShane LM et al (2003) Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 100(18):10393–10398 (10.1073/pnas.1732912100) / Proc Natl Acad Sci USA by C Sotiriou (2003)
  5. van ‘t Veer LJ, Dai H, van de Vijver MJ et al (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415(6871):530–536 (10.1038/415530a) / Nature by LJ ‘t Veer van (2002)
  6. Wang Y, Klijn JG, Zhang Y et al (2005) Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365(9460):671–679 (10.1016/S0140-6736(05)17947-1) / Lancet by Y Wang (2005)
  7. van de Vijver MJ, He YD, van ‘t Veer LJ et al (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347(25):1999–2009 (10.1056/NEJMoa021967) / N Engl J Med by MJ Vijver van de (2002)
  8. Jansen MP, Foekens JA, van Staveren IL et al (2005) Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. J Clin Oncol 23(4):732–740 (10.1200/JCO.2005.05.145) / J Clin Oncol by MP Jansen (2005)
  9. Paik S, Shak S, Tang G et al (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351(27):2817–2826 (10.1056/NEJMoa041588) / N Engl J Med by S Paik (2004)
  10. Ma XJ, Wang Z, Ryan PD et al (2004) A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 5(6):607–616 (10.1016/j.ccr.2004.05.015) / Cancer Cell by XJ Ma (2004)
  11. Reid JF, Lusa L, De Cecco L et al (2005) Limits of predictive models using microarray data for breast cancer clinical treatment outcome. J Natl Cancer Inst 97(12):927–930 (10.1093/jnci/dji153) / J Natl Cancer Inst by JF Reid (2005)
  12. Goetz MP, Suman VJ, Ingle JN et al (2006) A two-gene expression ratio of homeobox 13 and interleukin−17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen. Clin Cancer Res 12(7 Pt 1):2080–2087 (10.1158/1078-0432.CCR-05-1263) / Clin Cancer Res by MP Goetz (2006)
  13. Ma XJ, Hilsenbeck SG, Wang W et al (2006) The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. J Clin Oncol 24(28):4611–4619 (10.1200/JCO.2006.06.6944) / J Clin Oncol by XJ Ma (2006)
  14. Swedish Breast Cancer Cooperative Group (1996) Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. J Natl Cancer Inst 88(21):1543–1549 (10.1093/jnci/88.21.1543) / J Natl Cancer Inst by Swedish Breast Cancer Cooperative Group (1996)
  15. Ryden L, Jonsson PE, Chebil G, et al (2005) Two years of adjuvant tamoxifen in premenopausal patients with breast cancer: a randomised, controlled trial with long-term follow-up. Eur J Cancer 41(2):256–264 (10.1016/j.ejca.2004.06.030) / Eur J Cancer by L Ryden (2005)
  16. Fernö M, Stål O, Baldetorp B et al (2000) Results of two or five years of adjuvant tamoxifen correlated to steroid receptor and S-phase levels. South Sweden Breast Cancer Group, and South–East Sweden Breast Cancer Group. Breast Cancer Res Treat 59(1):69–76 (10.1023/A:1006332423620) / Breast Cancer Res Treat by M Fernö (2000)
  17. Stål O, Borg Å, Fernö M et al (2000) ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancer. Ann Oncol 11(12):1545–1550 (10.1023/A:1008313310474) / Ann Oncol by O Stål (2000)
  18. Edwards S, Campbell C, Flohr P, et al (2005) Expression analysis onto microarrays of randomly selected cDNA clones highlights HOXB13 as a marker of human prostate cancer. Br J Cancer 92(2):376–381 (10.1038/sj.bjc.6602261) / Br J Cancer by S Edwards (2005)
  19. Zhao Y, Yamashita T, Ishikawa M (2005) Regulation of tumor invasion by HOXB13 gene overexpressed in human endometrial cancer. Oncol Rep 13(4):721–726 / Oncol Rep by Y Zhao (2005)
  20. Lopez R, Garrido E, Pina P et al (2006) HOXB homeobox gene expression in cervical carcinoma. Int J Gynecol Cancer 16(1):329–335 (10.1111/j.1525-1438.2006.00350.x) / Int J Gynecol Cancer by R Lopez (2006)
  21. Okuda H, Toyota M, Ishida W, et al (2006) Epigenetic inactivation of the candidate tumor suppressor gene HOXB13 in human renal cell carcinoma. Oncogene 25(12):1733–1742 (10.1038/sj.onc.1209200) / Oncogene by H Okuda (2006)
  22. Jung C, Kim RS, Zhang H et al (2005) HOXB13 is downregulated in colorectal cancer to confer TCF4-mediated transactivation. Br J Cancer 92(12):2233–2239 (10.1038/sj.bjc.6602631) / Br J Cancer by C Jung (2005)
  23. Maeda K, Hamada J, Takahashi Y, et al (2005) Altered expressions of HOX genes in human cutaneous malignant melanoma. Int J Cancer 114(3):436–441 (10.1002/ijc.20706) / Int J Cancer by K Maeda (2005)
  24. Jung C, Kim RS, Lee SJ et al (2004) HOXB13 homeodomain protein suppresses the growth of prostate cancer cells by the negative regulation of T-cell factor 4. Cancer Res 64(9):3046–3051 (10.1158/0008-5472.CAN-03-2614) / Cancer Res by C Jung (2004)
  25. Jung C, Kim RS, Zhang HJ et al (2004) HOXB13 induces growth suppression of prostate cancer cells as a repressor of hormone-activated androgen receptor signaling. Cancer Res 64(24):9185–9192 (10.1158/0008-5472.CAN-04-1330) / Cancer Res by C Jung (2004)
  26. Rodriguez BAT, Jin VX, Cheng AS, et al (2006) HOXB13 is an estrogen receptor responsive gene preferentially methylated in ER-positive breast cancer. In: Proceedings of the 97th annual meeting, AACR, Washington, USA, 1–5 April 2006
  27. Cantile M, Pettinato G, Procino A, et al (2003) In vivo expression of the whole HOX gene network in human breast cancer. Eur J Cancer 39(2):257–264 (10.1016/S0959-8049(02)00599-3) / Eur J Cancer by M Cantile (2003)
  28. Apiou F, Flagiello D, Cillo C, et al (1996) Fine mapping of human HOX gene clusters. Cytogenet Cell Genet 73(1–2):114–115 (10.1159/000134320) / Cytogenet Cell Genet by F Apiou (1996)
  29. Shi Y, Ullrich SJ, Zhang J, et al (2000) A novel cytokine receptor–ligand pair. Identification, molecular characterization, and in vivo immunomodulatory activity. J Biol Chem 275(25):19167–19176 (10.1074/jbc.M910228199) / J Biol Chem by Y Shi (2000)
  30. Lee J, Ho WH, Maruoka M, et al (2001) IL−17E, a novel proinflammatory ligand for the IL−17 receptor homolog IL−17Rh1. J Biol Chem 276(2):1660–1664 (10.1074/jbc.M008289200) / J Biol Chem by J Lee (2001)
Dates
Type When
Created 18 years, 4 months ago (April 23, 2007, 6:13 a.m.)
Deposited 6 years, 3 months ago (May 30, 2019, 12:28 p.m.)
Indexed 1 year ago (Aug. 21, 2024, 10:47 p.m.)
Issued 18 years, 4 months ago (April 24, 2007)
Published 18 years, 4 months ago (April 24, 2007)
Published Online 18 years, 4 months ago (April 24, 2007)
Published Print 17 years, 8 months ago (Jan. 1, 2008)
Funders 0

None

@article{Jerevall_2007, title={Exploring the two-gene ratio in breast cancer—independent roles for HOXB13 and IL17BR in prediction of clinical outcome}, volume={107}, ISSN={1573-7217}, url={http://dx.doi.org/10.1007/s10549-007-9541-8}, DOI={10.1007/s10549-007-9541-8}, number={2}, journal={Breast Cancer Research and Treatment}, publisher={Springer Science and Business Media LLC}, author={Jerevall, Piiha-Lotta and Brommesson, Sara and Strand, Carina and Gruvberger-Saal, Sofia and Malmström, Per and Nordenskjöld, Bo and Wingren, Sten and Söderkvist, Peter and Fernö, Mårten and Stål, Olle}, year={2007}, month=apr, pages={225–234} }